	US 12,239,665 B2
	Methods of treating cancer using NK cells
Avinash Seth, San Dimas, CA (US); Nikko Lowe, City of Industry, CA (US); and Robert D. Fish, Irvine, CA (US)
Assigned to HONED LIFE SCIENCES, LLC, Irvine, CA (US)
Filed by Honed Life Sciences, LLC, Irvine, CA (US)
Filed on Dec. 8, 2022, as Appl. No. 18/077,938.
Application 18/077,938 is a division of application No. 16/831,244, filed on Mar. 26, 2020, granted, now 11,547,726.
Prior Publication US 2023/0109431 A1, Apr. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); A61K 35/545 (2015.01); A61P 35/00 (2006.01); C12N 5/074 (2010.01); C12N 5/0775 (2010.01); C12N 5/0783 (2010.01); C12N 5/0789 (2010.01)

CPC A61K 35/17 (2013.01) [A61K 35/545 (2013.01); A61P 35/00 (2018.01); C12N 5/0646 (2013.01); C12N 5/0647 (2013.01); C12N 5/0667 (2013.01); C12N 5/0696 (2013.01)]

7 Claims

1. A method of generating a CAR expressing NK cells (CARNK cells), comprising;

isolating endogenous NK cells from a cluster of adipocytes;

culturing non-fully differentiated stem cells;

inducing differentiation of non-fully differentiated stem cells into stem cell derived NK cells by co-culturing the cultured non-fully differentiated stem cells with the endogenous NK cells, wherein the non-fully differentiated stem cells and the endogenous NK cells are separated by a barrier when in culture; and

modifying the stem cell derived NK cells and the endogenous NK cells to express chimeric antigen receptor (CAR) to generate CARNK cells.